Johnson & Johnson (JNJ) Confirms Talks with Actelion on Possible Takeover
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $145.74 +0.67%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 3.4%
EPS Growth %: +1.1%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 3.4%
EPS Growth %: +1.1%
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) today confirmed it is engaged in preliminary discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) (OTC: ALIOY) regarding a potential transaction.
There can be no assurance any transaction will result from these discussions. Johnson & Johnson does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.
StreetInsider first reported on Wednesday that Actelion was a target of a takeover from a major U.S. pharmaceutical company. Bloomberg advanced the story on Thursday/Friday, saying Johnson & Johnson was the bidder.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Johnson & Johnson (JNJ) to Buy, 'Steady outlook, low expectations'
- Johnson & Johnson (JNJ) PT Lowered to $170 at BofA Securities
- Johnson & Johnson (JNJ) PT Lowered to $161 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
